TRIPLE NEGATIVE BREAST NEOPLASMS

This study is testing several new combinations of cancer drugs for women with advanced triple-negative breast cancer that has spread. The main goal is to see if these combinations can effectively control the cancer and are safe for patients who have not yet received treatment for…

This is an early-stage study to find a safe dose of a new drug called KFA115, both by itself and combined with an existing immunotherapy (pembrolizumab). It involves about 126 adults with various advanced cancers that have stopped responding to standard treatments. The main goal …

This early-stage study is testing a new investigational drug called BT8009 in people with advanced solid tumors that have a specific marker called Nectin-4. The main goals are to find a safe dose, see how the body processes the drug, and check for early signs that it can shrink t…

This study is testing whether adding a new drug called capivasertib to standard chemotherapy (paclitaxel) works better than chemotherapy alone for people with advanced triple-negative breast cancer. It involves 923 participants with cancer that has spread or cannot be surgically …

This study is testing whether adding the drug capecitabine to standard carboplatin-based chemotherapy works better for treating early triple-negative breast cancer before surgery. Researchers want to see if this combination helps more patients achieve a complete response, meaning…

This study tested whether adding the drug alpelisib to standard chemotherapy could better control advanced triple-negative breast cancer in patients with specific genetic changes in their tumors. It involved 137 patients and was a Phase 3 trial, but recruitment was halted early. …